Good Showing For Nycomed's COPD Drug Daxas
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.